Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?
Carlsbad, CA, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:…
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinsons Disease
Event to be held October 14th at 4 p.m. EST October 09,…
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
October 09, 2025 07:00 ET | Source: Axsome Therapeutics, Inc. NEW YORK,…
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
October 05, 2025 09:00 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass.,…
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025 16:01 ET | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass.,…
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in…
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2025 16:30 ET | Source: Fulcrum Therapeutics, Inc. CAMBRIDGE, Mass.,…